Insights into MMP-TIMP interactions

被引:154
作者
Bode, W
Fernandez-Catalan, C
Grams, F
Gomis-Rüth, FX
Nagase, H
Tschesche, H
Maskos, K
机构
[1] Max Planck Inst Biochem, D-82152 Martinsried, Germany
[2] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA
[3] Univ Bielefeld, Abt Biochem 1, D-33615 Bielefeld, Germany
来源
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS | 1999年 / 878卷
关键词
D O I
10.1111/j.1749-6632.1999.tb07675.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The proteolytic activity of the matrix metalloproteinases (MMPs) involved in extracellular matrix degradation must be precisely regulated by their endogenous protein inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Disruption of this balance can result in serious diseases such as arthritis and tumor growth and metastasis, Knowledge of the tertiary structures of the proteins involved in such processes is crucial for understanding their functional properties and to interfere with associated dysfunctions, Within the last few years, several three-dimensional structures have been determined showing the domain organization, the polypeptide fold, and the main specificity determinants of the MMPs. Complexes of the catalytic MMP domains with various synthetic inhibitors enabled the structure-based design and improvement of high-affinity ligands, which might be elaborated into drugs, Very recently, structural information also became available for some TIMP structures and MMP-TIMP complexes, and these new data elucidated important structural features that govern the enzyme-inhibitor interaction.
引用
收藏
页码:73 / 91
页数:19
相关论文
共 73 条
  • [1] THE GENE STRUCTURE OF TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP)-3 AND ITS INHIBITORY ACTIVITIES DEFINE THE DISTINCT TIMP GENE FAMILY
    APTE, SS
    OLSEN, BR
    MURPHY, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) : 14313 - 14318
  • [2] CRYSTAL-STRUCTURE OF A COMPLEX BETWEEN SERRATIA-MARCESCENS METALLOPROTEASE AND AN INHIBITOR FROM ERWINIA-CHRYSANTHEMI
    BAUMANN, U
    BAUER, M
    LETOFFE, S
    DELEPELAIRE, P
    WANDERSMAN, C
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1995, 248 (03) : 653 - 661
  • [3] STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME
    BECKER, JW
    MARCY, AI
    ROKOSZ, LL
    AXEL, MG
    BURBAUM, JJ
    FITZGERALD, PMD
    CAMERON, PM
    ESSER, CK
    HAGMANN, WK
    HERMES, JD
    SPRINGER, JP
    [J]. PROTEIN SCIENCE, 1995, 4 (10) : 1966 - 1976
  • [4] Matrix metalloproteinase inhibitors 1998
    Beckett, RP
    Whittaker, M
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) : 259 - 282
  • [5] A HELPING HAND FOR COLLAGENASES - THE HEMOPEXIN-LIKE DOMAIN
    BODE, W
    [J]. STRUCTURE, 1995, 3 (06) : 527 - 530
  • [6] THE X-RAY CRYSTAL-STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN NEUTROPHIL COLLAGENASE INHIBITED BY A SUBSTRATE-ANALOG REVEALS THE ESSENTIALS FOR CATALYSIS AND SPECIFICITY
    BODE, W
    REINEMER, P
    HUBER, R
    KLEINE, T
    SCHNIERER, S
    TSCHESCHE, H
    [J]. EMBO JOURNAL, 1994, 13 (06) : 1263 - 1269
  • [7] STRUCTURE OF ASTACIN AND IMPLICATIONS FOR ACTIVATION OF ASTACINS AND ZINC-LIGATION OF COLLAGENASES
    BODE, W
    GOMISRUTH, FX
    HUBER, R
    ZWILLING, R
    STOCKER, W
    [J]. NATURE, 1992, 358 (6382) : 164 - 167
  • [8] ASTACINS, SERRALYSINS, SNAKE-VENOM AND MATRIX METALLOPROTEINASES EXHIBIT IDENTICAL ZINC-BINDING ENVIRONMENTS (HEXXHXXGXXH AND MET-TURN) AND TOPOLOGIES AND SHOULD BE GROUPED INTO A COMMON FAMILY, THE METZINCINS
    BODE, W
    GOMISRUTH, FX
    STOCKLER, W
    [J]. FEBS LETTERS, 1993, 331 (1-2) : 134 - 140
  • [9] STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN FIBROBLAST COLLAGENASE COMPLEXED WITH AN INHIBITOR
    BORKAKOTI, N
    WINKLER, FK
    WILLIAMS, DH
    DARCY, A
    BROADHURST, MJ
    BROWN, PA
    JOHNSON, WH
    MURRAY, EJ
    [J]. NATURE STRUCTURAL BIOLOGY, 1994, 1 (02): : 106 - 110
  • [10] Matrix metalloproteinase inhibitors in arthritis
    Bottomley, KM
    Johnson, WH
    Walter, DS
    [J]. JOURNAL OF ENZYME INHIBITION, 1998, 13 (02): : 79 - 101